Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial

[1]  D. Montefiori,et al.  Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial , 2022, Nature Medicine.

[2]  D. Montefiori,et al.  A Bivalent Omicron-Containing Booster Vaccine against Covid-19 , 2022, The New England journal of medicine.

[3]  H Zhao,et al.  Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants , 2022, Virology.

[4]  L. Poon,et al.  Homologous and heterologous boosting with CoronaVac and BNT162b2: a randomized trial (the Cobovax study) , 2022, medRxiv.

[5]  H. Kim,et al.  Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules , 2022, Frontiers in Cellular and Infection Microbiology.

[6]  Xi Chen,et al.  A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains , 2022, Journal of clinical medicine.

[7]  Jue Liu,et al.  Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis , 2022, Vaccines.

[8]  Guizhen Wu,et al.  Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial , 2022, Nature Communications.

[9]  Diane J Post,et al.  Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant , 2022, Cell Reports Medicine.

[10]  E. Tartour,et al.  Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine , 2022, medRxiv.

[11]  Yang Wang,et al.  A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants , 2022, Vaccines.

[12]  J. Qu,et al.  Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern , 2022, Nature communications.

[13]  K. Warren,et al.  Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2 , 2022, Journal of Clinical Virology.

[14]  J. Haughney,et al.  Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. , 2022, Journal of Infection.

[15]  S. Coppens,et al.  Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant , 2022, NPJ vaccines.

[16]  Y. Maor,et al.  Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine , 2022, Nature Communications.

[17]  K. Swanson,et al.  Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 , 2022, Cell Host & Microbe.

[18]  J. Mascola,et al.  SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination , 2022, The New England journal of medicine.

[19]  L. Poon,et al.  Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination , 2022, Nature Medicine.

[20]  G. Screaton,et al.  Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.

[21]  J. Mascola,et al.  Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization , 2021, medRxiv.

[22]  Wen Zheng,et al.  Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials , 2021, The Lancet Infectious Diseases.

[23]  Scott M Elliott,et al.  Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.

[24]  M. Dudek,et al.  Performance of the T-SPOTⓇ.COVID test for detecting SARS-CoV-2-responsive T cells , 2021, International Journal of Infectious Diseases.

[25]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[26]  E. Chu,et al.  Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies , 2021, Clinical chemistry and laboratory medicine.

[27]  Eric J Topol,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.

[28]  S. Grzesiek,et al.  Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. , 2004, Journal of molecular biology.